Inventor · disambiguated record
Jessica Teeling
Also filed as: TEELING JESSICA
9 granted patents·4 pending applications·129 citations·filing 2003–2022
90Inventor score
Top patents by PatentIndex Score
13 records- 0193US7282568B2Human monoclonal antibodies against interleukin 8 (IL-8)GENMAB AS·Filed 2003·Granted Oct 16, 2007·39 cites·23 claims
- 0292US11339215B2Methods of treating cancer with human monoclonal antibodies against interleukin 8 (IL-8)CORMORANT PHARMACEUTICALS AB·Filed 2019·Granted May 24, 2022·4 cites·19 claims
- 0391US7850962B2Human monoclonal antibodies against CD20GENMAB AS·Filed 2005·Granted Dec 14, 2010·27 cites·49 claims
- 0489US8529902B2Human monoclonal antibodies against CD20TEELING JESSICA·Filed 2003·Granted Sep 10, 2013·36 cites·5 claims
- 0588US7622559B2Human monoclonal antibodies against interleukin 8 (IL-8)GENMAB AS·Filed 2007·Granted Nov 24, 2009·7 cites·15 claims
- 0687US8105588B2Human monoclonal antibodies against interleukin 8 (IL-8)TEELING JESSICA·Filed 2009·Granted Jan 31, 2012·7 cites·22 claims
- 0784US8603469B2Methods of treating cancer with human monoclonal antibodies against interleukin 8TEELING JESSICA·Filed 2011·Granted Dec 10, 2013·5 cites·23 claims
- 0883US10253093B2Human monoclonal antibodies against interleukin 8 (IL-8)CORMORANT PHARMACEUTICALS AB·Filed 2018·Granted Apr 9, 2019·2 cites·15 claims
- 0982US10066012B2Human monoclonal antibodies against interleukin 8 (IL-8)CORMORANT PHARMACEUTICALS AB·Filed 2016·Granted Sep 4, 2018·2 cites·15 claims
- 1080US2023042255A1Human monoclonal antibodies against interleukin 8 (il-8)CORMORANT PHARMACEUTICALS AB·Filed 2022·Application pending·0 cites
- 1168US2020317799A1Human Monoclonal Antibodies Against CD20GENMAB AS·Filed 2019·Application pending·0 cites
- 1265US2014170156A1Human monoclonal antibodies against interleukin 8 (il-8)GENMAB AS·Filed 2013·Application pending·0 cites
- 1355US2014093454A1Human Monoclonal Antibodies Against CD20GENMAB AS·Filed 2013·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →